Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial

MLA

Tan Dat Nguyen, et al. “Five Year Letrozole versus Placebo in BRCA1/2 Germline Mutations Carriers: Final Results of LIBER, a Double-Blind Randomized Phase III Breast Cancer Prevention Trial.” Journal of Clinical Oncology, vol. 38, May 2020, p. 1534. EBSCOhost, https://doi.org/10.1200/jco.2020.38.15_suppl.1534.

APA

Tan Dat Nguyen, Chabbert-Buffet Nathalie, Capucine Delnatte, Audrey Mailliez, Isabelle Tennevet, Jérôme Lemonnier, Pascaline Berthet, Pascale This, L. Roca, Virginie Galibert, Paul Gesta, Suzette Delaloge, Pascal Pujol, Jean-Pierre Fricker, Jean Chiesa, Alain Lortholary, Hélène Dreyfus, Laurence Venat-Bouvet, Catherine Dugast, & Christine Lasset. (2020). Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial. Journal of Clinical Oncology, 38, 1534. https://doi.org/10.1200/jco.2020.38.15_suppl.1534

Chicago

Tan Dat Nguyen, Chabbert-Buffet Nathalie, Capucine Delnatte, Audrey Mailliez, Isabelle Tennevet, Jérôme Lemonnier, Pascaline Berthet, et al. 2020. “Five Year Letrozole versus Placebo in BRCA1/2 Germline Mutations Carriers: Final Results of LIBER, a Double-Blind Randomized Phase III Breast Cancer Prevention Trial.” Journal of Clinical Oncology 38 (May): 1534. doi:10.1200/jco.2020.38.15_suppl.1534.